pfizer china - Search News

News

Pfizer Strikes Deal With China's 3SBio

Reuters on MSN · 2d

Pfizer in deal with China's 3SBio to license cancer drug candidate, take equity stake

U.S. drugmaker Pfizer said it would license an experimental cancer treatment from China's 3SBio Inc , paying $1.25 billion upfront and up to another $4.8 billion if developmental milestones are met.

Yahoo Finance · 2d

Pfizer Inc. (PFE) Inks $6 Billion Cancer Drug Licensing Agreement with China’s 3SBio

Pfizer Inc. (NYSE:PFE) announced it had entered into a licensing agreement valued at approximately $6 billion with Chinese biopharmaceutical firm 3SBio Inc. for the development, production, and commercialization of a potential cancer treatment.

CNBC on MSN · 1d

Pfizer strikes deal with China's 3SBio to license cancer drug

Meghan Markle’s Concert Photos Include a Hidden Tribute to Princess Lilibet Stephen Colbert Loves His Audience's Reaction To 'Out Of Nowhere' Trump Moment Colorado Passes Law to Officially Allow Kei Cars Starting in 2027 Nasa warns of huge solar flares causing blackouts on Earth 'Flamethrower' robots are now officially a part of Ukraine's war

BioPharma Dive1d

Pfizer buys into PD-1/VEGF competition with 3SBio deal

Pfizer will pay China’s 3SBio $1.25 billion up front to access a cancer drug that could rival Akeso and Summit’s closely ...

Fierce Biotech2d

Pfizer pays 3SBio $1.25B for PD-1xVEGF bispecific, joining red-hot race with BioNTech, Merck

Pfizer has joined the PD-1xVEGF bispecific gold rush. The Big Pharma is paying 3SBio $1.25 billion upfront for ex-China ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results